Responses
Regular and young investigator award abstracts
Clinical trials in progress
388 Preliminary results from KEYNOTE-A36, a study of GB1275, a first-in-class oral CD11b modulator, alone and with pembrolizumab or chemotherapy in specified advanced solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.
